Pfizer’s Dr. Megan O’Meara on developing cancer treatments of tomorrow
Dr. Megan O’Meara, Head of Early Stage Development at Pfizer, is driving breakthrough cancer treatments while championing women in Science, Technology, Engineering, and Mathematics (STEM). With a passion for innovation and mentorship, she’s working to advance cancer research while paving the way for future generations of female scientists.
From developing next-generation cancer therapies to advocating for inclusivity in research, Megan is committed to making an impact. In a recent interview with the Los Angeles Times, she shares how her career in oncology took shape, the challenges women in STEM still face, and the exciting progress happening at Pfizer to bring better treatment options to people with cancer.
Explore related topics
Who is at risk for lung cancer?
Learn about the factors that can increase your risk of developing lung cancer and how to reduce them.
How antibody-drug conjugates (ADCs) might change treatment
Antibody-drug conjugates are changing the landscape of cancer treatments.
Can AI help detect breast cancer early?
Studies are exploring whether AI can detect breast cancer faster and more accurately than current methods.